Maria Mancini
Chief Operating Officer bei CHAMPIONS ONCOLOGY, INC.
Profil
Maria Mancini is currently the Chief Operating Officer at Champions Oncology, Inc. She previously worked as the Research Director at Biomodels LLC from 2011 to 2015.
Dr. Mancini holds a doctorate degree from the University of Maine.
Aktive Positionen von Maria Mancini
Unternehmen | Position | Beginn |
---|---|---|
CHAMPIONS ONCOLOGY, INC. | Chief Operating Officer | - |
Ehemalige bekannte Positionen von Maria Mancini
Unternehmen | Position | Ende |
---|---|---|
Biomodels LLC
Biomodels LLC BiotechnologyHealth Technology Biomodels LLC offers customized solutions for the development of disease models in the fields of biology, behavior, and neuroscience. Biomodels is based in Boston, MA and was founded in 1997 with the aim of creating a more useful interface between leading academic researchers and the pharmaceutical industry. The private company provides a wide range of behavioral tests for examining treatment for neurological disorders. The company has developed several models of fibrosis to reflect common inflammatory diseases. The company also offers in vitro models for drug response assessment, metabolic disease studies, microbiome research services, and preclinical research services for cancer, radiation countermeasures, and inflammatory diseases. | Chief Tech/Sci/R&D Officer | 01.03.2015 |
Ausbildung von Maria Mancini
University of Maine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
CHAMPIONS ONCOLOGY, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Biomodels LLC
Biomodels LLC BiotechnologyHealth Technology Biomodels LLC offers customized solutions for the development of disease models in the fields of biology, behavior, and neuroscience. Biomodels is based in Boston, MA and was founded in 1997 with the aim of creating a more useful interface between leading academic researchers and the pharmaceutical industry. The private company provides a wide range of behavioral tests for examining treatment for neurological disorders. The company has developed several models of fibrosis to reflect common inflammatory diseases. The company also offers in vitro models for drug response assessment, metabolic disease studies, microbiome research services, and preclinical research services for cancer, radiation countermeasures, and inflammatory diseases. | Health Technology |